Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| TMC435HPC4013 | Other Identifier | Janssen-Cilag Ltd. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to describe: 1) the clinical profile, past and current management of participants with hepatitis C in Brazil reference centers; 2) the current situation about demographics characteristics, liver disease progression and clinical outcomes in Brazilian Hepatitis C virus (HCV) participants naive, in treatment and previously exposed to antiviral treatment without sustained virological response (SVR).
This is an observational, non-interventional, cross-sectional, multicenter study to describe demographic characteristics, treatment performed and clinical outcomes of Brazilian participants with HCV chronic infection in about 12 Brazilian reference centers. It will expect that approximately 2000 participants will be enrolled in the study. Analysis set will consist of participants with HCV chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype. The study related data will be collected from the medical records in the predesigned electronic Case Report Form (eCRF).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Brazilian participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with chronic hepatitis C infection | Data will be collected through medical records of the participants. | Day 1 |
| Date of last visit | Day 1 | |
| Number of Participants with chronic hepatitis C infection Reported Based on City and States | Data will be collected through medical records of the participants. | Day 1 |
| Number of Participants with chronic hepatitis C infection Based on precedence | Data will be collected through medical records of the participants. | Day 1 |
| Mean Age of Participants with chronic hepatitis C infection | Data will be collected through medical records of the participants. | Day 1 |
| Number of Males and Females with chronic hepatitis C infection | Data will be collected through medical records of the participants. | Day 1 |
| Number of participants with chronic hepatitis C infection Reported Based on Race | Data will be collected through medical records of the participants. | Day 1 |
| Mode of Hepatitis C virus (HCV) transmission | Data will be collected through medical records of the participants. Mode of HCV transmission route (unsafe injections, hemodialysis, infection drug use, blood transfusion, sexual transmission, vertical transmission, unknown, other) will be analysed by number of participants infected with HCV per transmission route. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Analysis set will consist of participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen-Cilag Ltd. Clinical Trial | Janssen-Cilag Ltd. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Goiânia | Brazil | |||||
Not provided
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 1 |
| Duration of diagnosis of chronic hepatitis C infection | Data will be collected through medical records of the participants. | Day 1 |
| HCV genotype and subtype | Data will be collected through medical records of the participants. | Day 1 |
| Liver characteristics: Number of Participants with extra hepatic manifestations | Data will be collected through medical records of the participants. Presence or absence of extra hepatic manifestations (cryoglobulinemia, lymphoma, Sjogren syndrome, glomerulopathy, Porphyria cutanea tarda, liquen planus, diabetes mellitus, thyroiditis, arthralgia). | Day 1 |
| Liver characteristics: Number of Participants with presence of comorbidities | Data will be collected through medical records of the participants. Presence of comorbidities (amount of alcohol ingestion, metabolic syndrome, hepatocellular carcinoma, organ transplantation, diabetes, immunodeficiency, renal insufficiency and dialysis, use of drugs) will be collected. | Day 1 |
| Liver characteristics: Model for End-Stage Liver Disease (MELD) Score and Child Pugh score | MELD is a scoring system for assessing the severity of chronic liver disease. Child-Pugh classification assesses the prognosis of chronic liver disease by 5 clinical measures, scored 1-3 each (most severe derangement=3). Score range: 5 (best prognosis) to 15 (worst prognosis). | Day 1 |
| Liver characteristics: Number of Participants with Fibrosis based on Fibroscan | Data will be collected through medical records of the participants. | Day 1 |
| Number of Participants with Coinfections | Data will be collected through medical records of the participants. | Day 1 |
| HCV treatment status on Day 1: Percentage of participants receiving antiviral treatment | Data will be collected through medical records of the participants. | Day 1 |
| HCV treatment status on Day 1: Causes of interruption in treatment | Data will be collected through medical records of the participants. Causes of interruption to antiviral therapy will be collected and reported. | Day 1 |
| HCV treatment status on Day 1: Number of participants treated without Sustained Virological Response (SVR) | Data will be collected through medical records of the participants. | Day 1 |
| Treatment regimen | The drugs used and time of treatment will be collected through medical records of the participants. | Day 1 |
| Number of participants with Adverse Events (AEs) | Day 1 |
| Porto Alegre |
| Brazil |
| Porto Velho | Brazil |
| Recife | Brazil |
| Rio Branco | Brazil |
| Rio de Janeiro | Brazil |
| Salvador | Brazil |
| São Paulo | Brazil |
| D014777 |
| Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |